23andMe is passionate about making discoveries that will benefit you.
We give individuals access to their DNA data while in turn translating information they’ve volunteered into meaningful genetic discoveries.
Today we’re announcing the acquisition of CureTogether, Inc.
a company that we’ve admired for creating communities of people who can share information about their health conditions, support each other and together discover new insights in managing their health.
The acquisition — as well as the addition to our team of its two co-founders, Daniel Reda and Alexandra Carmichael — will improve our own ability to gather data for research and give customers more tools to explore and participate in online communities.
CureTogether’s core mission of enabling people to share their health information as a way to collectively gain new insight into various diseases is aligned with 23andMe’s own crowd-sourced research model. CureTogether, with more than 25,000 members, has gathered nearly four million data points on 576 different medical conditions. Welcoming in those users and the data they’ve contributed to research will improve the important work we are already doing.
At 23andMe, we’ve learned that the quality of our research communities — how engaged and active they are — is vital for quality research.
Our research model has already made significant breakthroughs in the study of Parkinson’s disease, and we are heartened by the progress we’re making in Sarcoma and in Myeloproliferative Neoplasms.
23andMe puts power in the hands of patients to participate in research and accelerate new discoveries. The more people who participate, and the more engaged they are, the more powerful the research.
In this, the CureTogether community is a model for our own 23andMe research community. We’re all tring to find cures. Together, we can make even more of a difference.